Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid
Six consecutive patients with promyelocytic leukaemia displaying the PML/RAR‐α fusion messenger ribonucleic acid (mRNA) – the molecular marker of the disease – were prospectively treated with all‐trans retinoic acid: Haematological complete remission was achieved in all of them. However, in three of...
Gespeichert in:
| Veröffentlicht in: | Clinical and laboratory haematology 1998-06, Vol.20 (3), p.173-176 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 176 |
|---|---|
| container_issue | 3 |
| container_start_page | 173 |
| container_title | Clinical and laboratory haematology |
| container_volume | 20 |
| creator | RUIZ-ARGÜELLES, G. J. GARCÉS-EISELE, J. RUIZ-ARGÜELLES, A. |
| description | Six consecutive patients with promyelocytic leukaemia displaying the PML/RAR‐α fusion messenger ribonucleic acid (mRNA) – the molecular marker of the disease – were prospectively treated with all‐trans retinoic acid: Haematological complete remission was achieved in all of them. However, in three of them the PML/RAR‐α mRNA persisted. Subsequent treatment with ablative chemotherapy rendered the molecular remission in all cases. Two of the patients that did not achieve the molecular remission with ATRA were autografted with peripheral blood stem cells after clearing the PML/RAR‐α fusion mRNA. One patient with tretinoin‐induced molecular remission relapsed two years after diagnosis and died; the remaining five survive in complete haematological and molecular remission for periods ranging from 405 to 1695 days. Additional studies are needed to clarify the significance of the molecular follow‐up of patients with PML. |
| doi_str_mv | 10.1046/j.1365-2257.1998.00107.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80031933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80031933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3637-f8e03c3889254e706682b64e5406a88da8c7dd43ceb6f1b202f1c8fb9f689b563</originalsourceid><addsrcrecordid>eNqNkM2O0zAURi0EGsrAIyBlgdgl-Cdx7AULmMLMoM4wI4FYWo5zLdxxmmI7avv2uKTqmtW19J3vXusgVBBcEVzzD-uKMN6UlDZtRaQUFcYEt9X-GVqcg-dogUlNSima-iV6FeM6Q4y07QW6kFwQytgC6bvRg5m8DoUdvR935bQtRltsdXKwSbHYufS72IZxOIAfzSE5U3iYnjQMThcpgE7Qz5D2vkxBb2IRILnNmEltXP8avbDaR3hzmpfo59cvP65uytX369urT6vSMM7a0grAzDAhJG1qaDHngna8hqbGXAvRa2Havq-ZgY5b0lFMLTHCdtJyIbuGs0v0ft6bP_tngpjU4KIB7_UGxikqgTEjkrEMihk0YYwxgFXb4AYdDopgdbSr1uooUR0lqqNd9c-u2ufq29ONqRugPxdPOnP-7pTraLS32YZx8YxRRmtJRcY-ztjOeTj893l1-211k1-5X859FxPsz30dnhRvWduoX_fXakmWnx9Xcqke2F9aaKWh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80031933</pqid></control><display><type>article</type><title>Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>RUIZ-ARGÜELLES, G. J. ; GARCÉS-EISELE, J. ; RUIZ-ARGÜELLES, A.</creator><creatorcontrib>RUIZ-ARGÜELLES, G. J. ; GARCÉS-EISELE, J. ; RUIZ-ARGÜELLES, A.</creatorcontrib><description>Six consecutive patients with promyelocytic leukaemia displaying the PML/RAR‐α fusion messenger ribonucleic acid (mRNA) – the molecular marker of the disease – were prospectively treated with all‐trans retinoic acid: Haematological complete remission was achieved in all of them. However, in three of them the PML/RAR‐α mRNA persisted. Subsequent treatment with ablative chemotherapy rendered the molecular remission in all cases. Two of the patients that did not achieve the molecular remission with ATRA were autografted with peripheral blood stem cells after clearing the PML/RAR‐α fusion mRNA. One patient with tretinoin‐induced molecular remission relapsed two years after diagnosis and died; the remaining five survive in complete haematological and molecular remission for periods ranging from 405 to 1695 days. Additional studies are needed to clarify the significance of the molecular follow‐up of patients with PML.</description><identifier>ISSN: 0141-9854</identifier><identifier>EISSN: 1365-2257</identifier><identifier>DOI: 10.1046/j.1365-2257.1998.00107.x</identifier><identifier>PMID: 9681233</identifier><identifier>CODEN: CLHAD3</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; all-trans retinoic acid ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - genetics ; Bone Marrow - chemistry ; Bone Marrow - pathology ; Chemotherapy ; Child ; Evaluation Studies as Topic ; Female ; Follow-Up Studies ; Humans ; Leukaemia ; Leukemia, Promyelocytic, Acute - blood ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukemia, Promyelocytic, Acute - genetics ; Leukemia, Promyelocytic, Acute - pathology ; Male ; Medical sciences ; Middle Aged ; molecular ; Neoplasm Proteins - genetics ; Neoplasm, Residual ; Neoplastic Stem Cells - chemistry ; Oncogene Proteins, Fusion - genetics ; Pharmacology. Drug treatments ; Polymerase Chain Reaction ; promyelocytic ; Remission Induction ; RNA, Messenger - analysis ; RNA, Neoplasm - analysis ; Treatment Outcome ; Tretinoin - therapeutic use</subject><ispartof>Clinical and laboratory haematology, 1998-06, Vol.20 (3), p.173-176</ispartof><rights>Blackwell Publishers Ltd</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3637-f8e03c3889254e706682b64e5406a88da8c7dd43ceb6f1b202f1c8fb9f689b563</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2257.1998.00107.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2257.1998.00107.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2324928$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9681233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUIZ-ARGÜELLES, G. J.</creatorcontrib><creatorcontrib>GARCÉS-EISELE, J.</creatorcontrib><creatorcontrib>RUIZ-ARGÜELLES, A.</creatorcontrib><title>Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid</title><title>Clinical and laboratory haematology</title><addtitle>Clin Lab Haematol</addtitle><description>Six consecutive patients with promyelocytic leukaemia displaying the PML/RAR‐α fusion messenger ribonucleic acid (mRNA) – the molecular marker of the disease – were prospectively treated with all‐trans retinoic acid: Haematological complete remission was achieved in all of them. However, in three of them the PML/RAR‐α mRNA persisted. Subsequent treatment with ablative chemotherapy rendered the molecular remission in all cases. Two of the patients that did not achieve the molecular remission with ATRA were autografted with peripheral blood stem cells after clearing the PML/RAR‐α fusion mRNA. One patient with tretinoin‐induced molecular remission relapsed two years after diagnosis and died; the remaining five survive in complete haematological and molecular remission for periods ranging from 405 to 1695 days. Additional studies are needed to clarify the significance of the molecular follow‐up of patients with PML.</description><subject>Adolescent</subject><subject>Adult</subject><subject>all-trans retinoic acid</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Bone Marrow - chemistry</subject><subject>Bone Marrow - pathology</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Leukaemia</subject><subject>Leukemia, Promyelocytic, Acute - blood</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukemia, Promyelocytic, Acute - genetics</subject><subject>Leukemia, Promyelocytic, Acute - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>molecular</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasm, Residual</subject><subject>Neoplastic Stem Cells - chemistry</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymerase Chain Reaction</subject><subject>promyelocytic</subject><subject>Remission Induction</subject><subject>RNA, Messenger - analysis</subject><subject>RNA, Neoplasm - analysis</subject><subject>Treatment Outcome</subject><subject>Tretinoin - therapeutic use</subject><issn>0141-9854</issn><issn>1365-2257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM2O0zAURi0EGsrAIyBlgdgl-Cdx7AULmMLMoM4wI4FYWo5zLdxxmmI7avv2uKTqmtW19J3vXusgVBBcEVzzD-uKMN6UlDZtRaQUFcYEt9X-GVqcg-dogUlNSima-iV6FeM6Q4y07QW6kFwQytgC6bvRg5m8DoUdvR935bQtRltsdXKwSbHYufS72IZxOIAfzSE5U3iYnjQMThcpgE7Qz5D2vkxBb2IRILnNmEltXP8avbDaR3hzmpfo59cvP65uytX369urT6vSMM7a0grAzDAhJG1qaDHngna8hqbGXAvRa2Havq-ZgY5b0lFMLTHCdtJyIbuGs0v0ft6bP_tngpjU4KIB7_UGxikqgTEjkrEMihk0YYwxgFXb4AYdDopgdbSr1uooUR0lqqNd9c-u2ufq29ONqRugPxdPOnP-7pTraLS32YZx8YxRRmtJRcY-ztjOeTj893l1-211k1-5X859FxPsz30dnhRvWduoX_fXakmWnx9Xcqke2F9aaKWh</recordid><startdate>199806</startdate><enddate>199806</enddate><creator>RUIZ-ARGÜELLES, G. J.</creator><creator>GARCÉS-EISELE, J.</creator><creator>RUIZ-ARGÜELLES, A.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199806</creationdate><title>Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid</title><author>RUIZ-ARGÜELLES, G. J. ; GARCÉS-EISELE, J. ; RUIZ-ARGÜELLES, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3637-f8e03c3889254e706682b64e5406a88da8c7dd43ceb6f1b202f1c8fb9f689b563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>all-trans retinoic acid</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Bone Marrow - chemistry</topic><topic>Bone Marrow - pathology</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Leukaemia</topic><topic>Leukemia, Promyelocytic, Acute - blood</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukemia, Promyelocytic, Acute - genetics</topic><topic>Leukemia, Promyelocytic, Acute - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>molecular</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasm, Residual</topic><topic>Neoplastic Stem Cells - chemistry</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymerase Chain Reaction</topic><topic>promyelocytic</topic><topic>Remission Induction</topic><topic>RNA, Messenger - analysis</topic><topic>RNA, Neoplasm - analysis</topic><topic>Treatment Outcome</topic><topic>Tretinoin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUIZ-ARGÜELLES, G. J.</creatorcontrib><creatorcontrib>GARCÉS-EISELE, J.</creatorcontrib><creatorcontrib>RUIZ-ARGÜELLES, A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and laboratory haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUIZ-ARGÜELLES, G. J.</au><au>GARCÉS-EISELE, J.</au><au>RUIZ-ARGÜELLES, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid</atitle><jtitle>Clinical and laboratory haematology</jtitle><addtitle>Clin Lab Haematol</addtitle><date>1998-06</date><risdate>1998</risdate><volume>20</volume><issue>3</issue><spage>173</spage><epage>176</epage><pages>173-176</pages><issn>0141-9854</issn><eissn>1365-2257</eissn><coden>CLHAD3</coden><abstract>Six consecutive patients with promyelocytic leukaemia displaying the PML/RAR‐α fusion messenger ribonucleic acid (mRNA) – the molecular marker of the disease – were prospectively treated with all‐trans retinoic acid: Haematological complete remission was achieved in all of them. However, in three of them the PML/RAR‐α mRNA persisted. Subsequent treatment with ablative chemotherapy rendered the molecular remission in all cases. Two of the patients that did not achieve the molecular remission with ATRA were autografted with peripheral blood stem cells after clearing the PML/RAR‐α fusion mRNA. One patient with tretinoin‐induced molecular remission relapsed two years after diagnosis and died; the remaining five survive in complete haematological and molecular remission for periods ranging from 405 to 1695 days. Additional studies are needed to clarify the significance of the molecular follow‐up of patients with PML.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9681233</pmid><doi>10.1046/j.1365-2257.1998.00107.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0141-9854 |
| ispartof | Clinical and laboratory haematology, 1998-06, Vol.20 (3), p.173-176 |
| issn | 0141-9854 1365-2257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80031933 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult all-trans retinoic acid Antineoplastic agents Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomarkers, Tumor - genetics Bone Marrow - chemistry Bone Marrow - pathology Chemotherapy Child Evaluation Studies as Topic Female Follow-Up Studies Humans Leukaemia Leukemia, Promyelocytic, Acute - blood Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - genetics Leukemia, Promyelocytic, Acute - pathology Male Medical sciences Middle Aged molecular Neoplasm Proteins - genetics Neoplasm, Residual Neoplastic Stem Cells - chemistry Oncogene Proteins, Fusion - genetics Pharmacology. Drug treatments Polymerase Chain Reaction promyelocytic Remission Induction RNA, Messenger - analysis RNA, Neoplasm - analysis Treatment Outcome Tretinoin - therapeutic use |
| title | Molecular follow-up of patients with promyelocytic leukaemia treated with all-trans retinoic acid |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A48%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20follow-up%20of%20patients%20with%20promyelocytic%20leukaemia%20treated%20with%20all-trans%20retinoic%20acid&rft.jtitle=Clinical%20and%20laboratory%20haematology&rft.au=RUIZ-ARG%C3%9CELLES,%20G.%20J.&rft.date=1998-06&rft.volume=20&rft.issue=3&rft.spage=173&rft.epage=176&rft.pages=173-176&rft.issn=0141-9854&rft.eissn=1365-2257&rft.coden=CLHAD3&rft_id=info:doi/10.1046/j.1365-2257.1998.00107.x&rft_dat=%3Cproquest_cross%3E80031933%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80031933&rft_id=info:pmid/9681233&rfr_iscdi=true |